Assess creatine testing, strength-training relevance, and body-mass tradeoffs without mistaking product quality for endurance benefits.
On September 24, 2026, The Workout Magazine published a guide to verifying creatine purity and quality. It outlined checks for product contents and contamination rather than treating the word “creatine” on a label as sufficient evidence. For endurance athletes, its most useful distinction is between a verified product and a supplement that fits the work you actually do.
That distinction deserves attention after 35. Maintaining strength and pursuing an aerobic race result are related ambitions, but they are not the same outcome. A purchasing decision should account for both without confusing them.
The guide’s central message is straightforward: quality verification asks whether a product contains what it claims and meets the limits covered by its tests. Performance evidence asks whether supplementation supports a particular training or racing goal. Passing the first test does not answer the second.
This was a product-verification guide, not a new performance trial. Its contribution is a framework for evaluating identity and potency alongside contamination controls and batch traceability. Those checks help assess the product rather than predict a finishing time.
The related performance evidence points toward a more specific use case. A review summarized by Holland & Barrett reported greater gains in lean tissue mass and upper- and lower-body strength when creatine accompanied resistance training than with resistance training alone. That makes strength development a more defensible reason to consider creatine than an assumed improvement in sustained aerobic performance.
The evidence limits belong together here. The older-adult findings come through a secondary summary that described the evidence as not conclusive. A separate endurance-focused secondary summary reported no improvement in endurance performance in a trained population, but the available material does not provide the full paper or enough protocol detail to generalize across events. Neither summary establishes the expected response of every endurance athlete aged 35 to 65.
The practical reading is conditional rather than contradictory. A supplement can have relevance to the strength component of an endurance program without having demonstrated value for the aerobic outcome that matters most on race day.
For the ambitious older athlete, the first question is not which powder has the strongest marketing claim. It is which part of the training program the supplement is intended to support.
The resistance-training findings summarized by Holland & Barrett provide the strongest rationale in this evidence packet. They concern muscle and strength outcomes alongside resistance exercise. They do not turn creatine into a substitute for that exercise.
For an endurance athlete who also pursues strength, this gives the decision a defined purpose. The relevant question becomes whether creatine supports that part of the program rather than whether it makes every training session better. Keeping protein and strength planning in the same conversation also helps keep a supplement from becoming the whole nutrition strategy.
The research packet identifies repeated high-intensity work as another reasonable context for consideration. That includes short hard intervals and repeated surges rather than almost exclusively steady aerobic work. The supporting argument is about the demands of the training, not the athlete’s endurance-sport label.
That distinction matters when setting expectations. Strength progression and repeatability during hard efforts are different outcomes from sustained aerobic performance. An athlete evaluating the former should not quietly substitute a hoped-for improvement in the latter.
The primary guide specifically flags possible water-weight implications. It advises weighing strength or repeated-high-intensity objectives against power-to-weight priorities. It does not provide a universal amount of weight gain, so a fixed prediction would be unjustified.
For a runner or cyclist whose event is sensitive to body mass, that tradeoff deserves attention from the outset. A strength-related improvement and a body-mass change need to be considered together. Looking at only the favorable measure would leave the decision incomplete.
Reendure’s position is that immediate performance and long-term athletic ambition deserve equal weight. Here, that means judging creatine against the training plan rather than letting a supplement determine the plan.
Once the training rationale is clear, the guide’s verification framework becomes useful. Its recommendation is to examine several independent dimensions rather than rely on front-of-pack language. Each document or test should answer an identifiable question.
The guide distinguishes checking what a product contains from checking how much it contains. It also recommends examining contaminants and manufacturing controls. A broad “tested” claim gives less information than documentation showing which questions were actually investigated.
Its testing framework assigns different methods to different tasks:
These names are useful for understanding a report’s scope. They are not interchangeable evidence of overall quality. The practical task is to connect the claimed result with the substance or contamination category being tested.
The guide also identifies creatinine as a degradation byproduct and suggests a level below 1% as a quality benchmark. That is the guide’s recommendation, not an established universal regulatory limit in the supplied evidence.
For athletes subject to anti-doping rules, the guide recommends checking certification databases such as NSF Certified for Sport or Informed Sport. The check should concern the exact product and batch rather than a general claim about the manufacturer.
Product flavor or formulation also matters to the match. A logo on a marketplace listing is not the same thing as confirming that the product being purchased appears in the relevant database. The guide also recommends retaining purchase and batch records.
This is a contamination-risk question. It should remain separate from the performance decision already made about the training goal.
The guide recommends requesting a certificate of analysis, or COA, preferably from an ISO 17025-accredited laboratory. The documentation should correspond to the specific product or batch being purchased.
Useful details include the laboratory identity and analytical methods. The test date should be clear. So should the acceptance criteria and reported results.
A manufacturer’s willingness to supply this material demonstrates transparency. However, a brand-supplied COA is not automatically equivalent to independent certification. Its scope and batch identity need to be verifiable before it carries much weight in the decision.
The guide also proposes an at-home dissolution check. That can reveal obvious clumping or poor dispersibility, but it cannot establish chemical purity or potency. It also cannot establish heavy-metal status or microbial safety, or rule out banned substances.
A product that disperses well can still have a problem that requires laboratory testing to detect. A legitimate product may also fail to dissolve completely in cool water. Appearance in a glass should therefore remain an observation rather than a quality verdict.
The practical implications in the research favor evaluation during training rather than immediately before an important race. They do not establish a universal race-day protocol. The purpose is to assess whether the supplement fits the athlete’s goals and response.
A useful evaluation keeps different outcomes separate:
These are questions to assess, not promised benefits. The research also identifies recovery between hard efforts as a possible measure to track. Recording it does not establish in advance that creatine will improve it.
From an editorial standpoint, changing several parts of a program at once makes the supplement’s contribution harder to interpret. Keeping the evaluation within a considered training transition gives the decision a clearer context. The aim is a useful conclusion rather than a collection of favorable impressions.
Medical decisions require a different conversation. Athletes with kidney disease or complex medication regimens should discuss suitability with a qualified clinician. The same applies when other medical conditions make supplementation a personal clinical decision.
Finally, creatine should remain one component of the wider plan. The research does not support replacing progressive training or adequate protein with it. Sleep and broader recovery decisions still belong in that plan rather than being pushed aside by a product purchase.
For endurance athletes over 35, creatine deserves consideration when it serves a defined strength or high-intensity goal, but verified product quality alone is not a reason to take it.
Follow ReEndure for practical insights on endurance training, recovery, nutrition and healthy aging. Stay connected for new articles, research led guidance and ideas to help you perform better for longer.
Read practical ideas on endurance training, recovery, nutrition and healthy aging to keep progressing for years to come.
Read the Blog